POSTER PRESENTATION ABSTRACTS
Please note: All posters will be displayed in Salons 10-12.

FRIDAY, 5:45-6:30 PM


Amri H, Pretner E, Li W, Brown R, Lin CS, Makariou E, DeFeudis FV, Drieu K, Papadopoulos, V.

Effects of Ginkgo biloba extract EGb 761 on tumor growth and metastasis: an adjuvant therapeutic alternative.

Department of Physiology and Biophysics, Georgetown University School of Medicine amrih@georgetown.edu

PURPOSE: This study investigates the effect of EGb 761 extract (used in its injectable form, i.e. IPS 200, which is devoid of cytotoxic proanthocyanidins) on cell growth and proliferation in human cell lines of different ontogeny over-expressing PBR, and on tumor growth and metastasis in nude mice. Ginkgo biloba's medicinal value has been extensively described in the Chinese pharmacopoeia, especially in the context of cardiovascular and respiratory disease states as well as elevated serum cholesterol levels. The peripheral-type benzodiazepine receptor (PBR) is defined as a cholesterol transport channel, which is over-expressed in a number of cancer cell lines and certain types of malignant tumors. Our group has previously demonstrated that standardized Ginkgo biloba extract EGb 761 regulates PBR at the cellular, molecular, and gene _expression levels.

METHODS: Immunocytochemistry, radioligand-binding methods, cell proliferation and viability assays, quantitative PCR, as well as apoptosis assays were used for the in vitro studies. Evaluation of tumor growth and metastasis, including MRI imaging, were used as in vivo outcome measures. One-way analysis of variance and unpaired t-test were performed using the InStat program.

RESULTS: Treatment with EGb 761 inhibited the proliferation of human breast cancer MDA-MB-231, glioblastoma U-87, and hepatocarcinoma HepG2 and Hep3B cell lines in a dose dependent manner. Total PBR mRNA levels in MDA-MB-231, U-87, and HT-29 (colon cancer) cell lines were decreased upon treatment, indicating that EGb 761 acts via the modification of PBR _expression. In vivo treatment with EGb 761 led to dose-dependent decreases in xenograft growth of both MDA-MB-231 breast cancer and U-87 glioblastoma cell lines in nude mice, although the effects in the latter were not maintained beyond 50 days of treatment. Results obtained with pretreated MDA-MB-231 xenografts indicated pronounced inhibition of tumor growth as verified by MRI imaging. Although the exact role of PBR in relation to the initiation and progression of various types of cancers remains to be defined, our results indicate that PBR over-_expression in certain cancer cells is related to an aggressive phenotype. Treatment with EGb 761 appears to oppose this aggressive phenotype by decreasing PBR over-_expression.

CONCLUSIONS: Ginkgo biloba standardized extract EGb 761 plays an anti-cancer role by regulating PBR _expression in both in vitro and in vivo models. We therefore conclude that EGb 761 may offer a useful adjuvant therapeutic approach in the prevention and treatment of certain cancers via its effects on invasiveness and metastatic spread.

 

Back